Home Stakeholders Health & Social Care Stakeholders ALV-B – Cancer treatment for dogs & cats

ALV-B – Cancer treatment for dogs & cats

ALV-B are enhancing veterinary medicine by creating a global centre of excellence through their research on experimental cancer treatment for dogs & cats

Cancer treatment in dogs and catsMuch like humans, pets get cancer too, and the scope of cancer treatments for dogs and cats is increasing in current times. The treatments for pets that get solid tumours typically consist of surgery, chemotherapy and radiation, or a combination of these.

Treatment methods related to immunotherapy have been increasing for humans for some time and we have now seen an unmet need for similar products in veterinary medicine. New research on pet cancer shows that experimental cancer treatments can have life-prolonging benefits, and are often seen to result in fewer side effects.


One of ALV-B’s main goals is to develop new immunotherapies for solid cancers in companion dogs. The treatments will be tailored for each individual patient and will serve as a supplement to standard cancer surgery as well as a substitute for the side-effect prone chemotherapy. ALV are currently developing treatments that can be administered at the local veterinary clinic and even applied to other pets as well.


Another important goal of ALV-B is to create a biobank of canine and feline cancers and normal tissues that will serve as a base for their research. They are also establishing primary cell lines from individual patients that can be used for research and drug testing.

Molecular profiles, Bioinformatics and Diagnostics

ALV-B are generating molecular profiles of the primary cell lines that they are establishing. These molecular profiles can then be used for research and to design new immunotherapies against cancer, as well as providing valuable information with a diagnostic value.

Molecular diagnostics can be very valuable in the clinic. However, there is a need for bioinformatic tools that are applicable to canine and feline genomes, transcriptomes and proteomes. There are currently very few of these. Designing new bioinformatic tools especially tailored to canine and feline cancer research is one of our goals. The number of public canine and feline molecular cancer-profiles is also far behind that for their human and murine counterparts. ALV-B are going to generate molecular data profiles and design bioinformatic tools that will speed up this type of research and contribute to the information exchange between various research organisations and communities.

Stakeholder Profiles